NCT02417142View on ClinicalTrials.gov

Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2020

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Exenatide

Exenatide SQ 2mg/week for 24 weeks.

DRUG

Placebo

Placebo SQ 1x/week for 24 weeks.

Trial Locations (1)

01605

UMass Medical School, Worcester

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

University of Massachusetts, Worcester

OTHER

NCT02417142 - Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter